These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 1525602

  • 1. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.
    Méresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L, Lemerle J.
    Bone Marrow Transplant; 1992 Aug; 10(2):135-41. PubMed ID: 1525602
    [Abstract] [Full Text] [Related]

  • 2. Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
    Cacchione A, LeMaitre A, Couanet DV, Benhamou E, Amoroso L, Simonnard N, Hartmann O.
    Bone Marrow Transplant; 2008 Oct; 42(7):449-54. PubMed ID: 18587430
    [Abstract] [Full Text] [Related]

  • 3. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
    Bouligand J, Boland I, Valteau-Couanet D, Deroussent A, Kalifa C, Hartmann O, Vassal G.
    Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.
    Bouligand J, Le Maitre A, Valteau-Couanet D, Grill J, Drouard-Troalen L, Paci A, Hartmann O, Benhamou E, Vassal G.
    Clin Pharmacol Ther; 2007 Oct; 82(4):402-9. PubMed ID: 17392724
    [Abstract] [Full Text] [Related]

  • 6. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
    Ozkaynak MF, Weinberg K, Kohn D, Sender L, Parkman R, Lenarsky C.
    Bone Marrow Transplant; 1991 Jun; 7(6):467-74. PubMed ID: 1908340
    [Abstract] [Full Text] [Related]

  • 7. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome.
    Brugieres L, Hartmann O, Benhamou E, Zafrani ES, Caillaud JM, Patte C, Kalifa C, Flamant F, Lemerle J.
    Bone Marrow Transplant; 1988 Jan; 3(1):53-8. PubMed ID: 3048471
    [Abstract] [Full Text] [Related]

  • 8. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.
    Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A, Lemerle J, Gouyette A, Hartmann O.
    Cancer Chemother Pharmacol; 1996 Jan; 37(3):247-53. PubMed ID: 8529285
    [Abstract] [Full Text] [Related]

  • 9. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, Galambrun C, Dai Q, Maire P, Jelliffe RW, Aulagner G.
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, Dupuis LL.
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy of low-dose heparin and prostaglandin E1 in the prevention of hepatic veno-occlusive disease after allogenic hematopoietic stem cell transplantation in children with beta-thalassemia major].
    Sun X, Hao WG, Liu S, Xia T, Liao C.
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Aug; 9(4):343-6. PubMed ID: 17706036
    [Abstract] [Full Text] [Related]

  • 12. Chronopharmacology of high-dose busulfan in children.
    Vassal G, Challine D, Koscielny S, Hartmann O, Deroussent A, Boland I, Valteau-Couanet D, Lemerle J, Lévi F, Gouyette A.
    Cancer Res; 1993 Apr 01; 53(7):1534-7. PubMed ID: 8453619
    [Abstract] [Full Text] [Related]

  • 13. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
    Lee JH, Choi SJ, Lee JH, Kim SE, Park CJ, Chi HS, Lee MS, Lee JS, Kim WK, Lee KH.
    Ann Hematol; 2005 May 01; 84(5):321-30. PubMed ID: 15580502
    [Abstract] [Full Text] [Related]

  • 14. Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment.
    Bajwa RP, Cant AJ, Abinun M, Flood TJ, Hodges S, Hale JP, Skinner R.
    Bone Marrow Transplant; 2003 Apr 01; 31(7):591-7. PubMed ID: 12692627
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J, Sender L, Secola R, Killen R, Millerick M, Murphy L, Cairo MS.
    Bone Marrow Transplant; 1996 Jul 01; 18(1):185-91. PubMed ID: 8832013
    [Abstract] [Full Text] [Related]

  • 16. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review).
    Vassal G.
    Anticancer Res; 1994 Jul 01; 14(6A):2363-70. PubMed ID: 7825973
    [Abstract] [Full Text] [Related]

  • 17. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA, Choroszy M, Danielson M, Przepiorka D, Chan KW.
    Bone Marrow Transplant; 2000 Sep 01; 26(5):463-70. PubMed ID: 11019834
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the effects of preconditioning regimens on hepatic veno-occlusive disease in mice after hematopoietic stem cell transplantation.
    Qiao J, Fu J, Fang T, Huang Y, Mi H, Yang N, Chen C, Xu K, Zeng L.
    Exp Mol Pathol; 2015 Feb 01; 98(1):73-8. PubMed ID: 25533545
    [Abstract] [Full Text] [Related]

  • 19. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institution.
    Kami M, Mori S, Tanikawa S, Akiyama H, Onozawa Y, Tanaka T, Okamoto R, Maeda Y, Sasaki T, Kaku H, Matsuura Y, Hiruma K, Sakamaki H.
    Bone Marrow Transplant; 1997 Sep 01; 20(5):397-402. PubMed ID: 9339756
    [Abstract] [Full Text] [Related]

  • 20. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
    Vaughan WP, Dennison JD, Reed EC, Klassen L, McGuire TR, Sanger WG, Kumar PP, Warkentin PI, Gordon BG, Bierman PJ.
    Bone Marrow Transplant; 1991 Dec 01; 8(6):489-95. PubMed ID: 1790429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.